Nureca Ltd. (NURECA) AI Stock Analysis

• Market Cap: ₹2.29B
• Dividend Yield: N/A
• Average Volume (3M): 9.27K
• Price to Earnings (P/E): 20.6
• Beta (1Y): 0.99
• Revenue Growth: 43.30%
• EPS Growth: N/A
• Country: IN
• Employees: 138
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 3.73
• Shares Outstanding: 9,541,920
• 10 Day Avg. Volume: 526
• 30 Day Avg. Volume: 9,266
• PEG Ratio: -1.76
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -9.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹249.00 ▼(-16.68% Downside)
• Action: Reiterated Date: 12/02/25
• Date: Action: Reiterated 12/02/25

Nureca Ltd.'s overall stock score is primarily influenced by its challenging financial performance, marked by negative profitability and cash flow issues. While technical analysis shows positive momentum, the high P/E ratio suggests overvaluation. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Low Leverage / Strong Equity

A very high equity ratio (≈92%) and favorable debt-to-equity indicate low financial leverage and limited fixed financing costs. This balance-sheet strength supports resilience through downturns, makes external funding less urgent, and preserves strategic optionality for 2–6 month initiatives or capex.

Recent Revenue Acceleration

Reported revenue growth above 50% signals meaningful demand traction for the company's product portfolio. Durable top-line expansion improves unit economics potential, aids scale benefits in distribution and marketing, and provides a foundation to recover margins if cost structure is reined in over coming quarters.

Branded D2C health/wellness model

Owning recognizable brands and selling home health and wellness devices via direct and online channels supports higher margin capture, control of customer experience, and repeat-purchase potential. Structural demand for at-home health tools underpins steady addressable-market growth over the medium term.

Negative Factors

Negative cash flow

Sustained negative operating and free cash flow undermines the firm's ability to self-fund working capital and capex, increasing reliance on external financing. Over months this constrains marketing, inventory investment and slows product rollout, raising execution risk and liquidity pressure.

Volatile / declining revenues

A pattern of revenue volatility and multi-year declines signals inconsistent demand, channel disruption or competitive pressure. This reduces predictability of cash generation and makes it harder to plan investment, hampering durable margin improvement and long-term strategic execution.

Negative operating profitability

A moderate gross margin (~38%) but negative EBIT and net losses indicate high operating cost or weak scale economics. Without structural cost reduction or improved mix, the firm cannot convert sales into sustainable profits, limiting free cash flow generation and funding for growth.

Nureca Ltd. Business Overview & Revenue Model

Company Description

Nureca Limited, a B2C company, engages in the home healthcare and wellness products business in India. It offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeter, glucose meter, and thermometer; orthopedic products, including massagers, pain monitors, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise, fitness tracking, and dental and personal care products. The company also provides mother and baby care products comprising baby feeding, carry cots, baby skincare, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG, fitness tracker, and smart weighing scale products. Nureca Limited offers its products under Dr Trust, Dr Physio, and Trumom brands. The company sells its products through third party e-commerce players, distributors, and retailers; and through its website, drtrust.in. Nureca Limited was incorporated in 2016 and is based in Chandigarh, India.

How the Company Makes Money

Nureca makes money primarily by selling branded health, wellness, and home-care products directly to consumers. Its revenue is generated from product sales under its owned/marketed brands (notably Dr Trust and Dr Physio) across online channels (e-commerce marketplaces and potentially its own web properties) and other retail/distribution routes. Earnings are driven by unit volumes and product mix across categories such as home health monitoring devices and wellness/fitness or therapy-oriented products. null

Nureca Ltd. Financial Statement Overview

Summary

Nureca Ltd. faces significant financial challenges with volatile revenue trends, negative profitability, and cash flow issues. While the balance sheet shows strong equity and low leverage, the overall financial health is compromised by operational inefficiencies and liquidity concerns.

Income Statement

Nureca Ltd. has shown volatile revenue trends with a decline in revenue from 2022 to 2025. The gross profit margin remains moderate at approximately 38% in 2025, but net profitability is a concern with fluctuating net income, swinging to losses in recent periods. The EBIT margin is negative, indicating operational challenges. EBITDA shows improvement in 2025 compared to previous years, but overall performance remains inconsistent.

Balance Sheet

Nureca Ltd.'s balance sheet showcases strong equity with a high equity ratio of around 92% in 2025, indicating low leverage. The debt-to-equity ratio is favorable, suggesting prudent debt management. However, declining total assets over recent periods may signal underlying issues in asset management or utilization.

Cash Flow

The cash flow analysis reveals a challenging financial position with negative free cash flow growth and operating cash flow. The free cash flow to net income ratio is unfavorable, highlighting inefficiencies in converting income to cash. Despite some capital investment, liquidity remains a concern.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.30B	1.10B	919.28M	1.11B	2.56B	2.13B
Gross Profit	439.25M	231.33M	311.42M	355.94M	1.23B	1.14B
EBITDA	82.58M	48.95M	2.41M	-79.04M	632.04M	642.33M
Net Income	41.07M	8.46M	-17.94M	-82.50M	449.60M	463.74M
Balance Sheet
Total Assets	2.25B	2.10B	2.05B	2.07B	2.19B	1.86B
Cash, Cash Equivalents and Short-Term Investments	87.40M	736.29M	1.44B	1.02B	927.10M	1.27B
Total Debt	53.92M	49.66M	25.16M	33.27M	44.05M	38.85M
Total Liabilities	259.46M	156.91M	120.54M	116.97M	159.32M	226.54M
Stockholders Equity	1.99B	1.94B	1.93B	1.95B	2.03B	1.63B
Cash Flow
Free Cash Flow	-10.02M	-234.06M	-37.98M	98.31M	-46.00M	341.40M
Operating Cash Flow	44.46M	-190.83M	-27.12M	102.27M	13.99M	348.67M
Investing Cash Flow	-67.25M	84.39M	175.76M	-164.56M	-30.89M	-1.10B
Financing Cash Flow	2.16M	-1.69M	-13.03M	-15.07M	-73.02M	923.39M

Nureca Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 298.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Negative. The current price of 298.85 is above the 20-day moving average (MA) of 269.64, above the 50-day MA of 280.70, and above the 200-day MA of 270.45, indicating a bearish trend. The MACD of -11.46 indicates Positive momentum. The RSI at 32.66 is Neutral, neither overbought nor oversold. The STOCH value of 9.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NURECA.

Nureca Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	65 Neutral	₹30.49B	19.90	―	1.70%	14.11%	7.47%
NURECA	57 Neutral	₹2.29B	20.62	―	―	43.30%	―
MOREPENLAB	57 Neutral	₹20.28B	20.54	―	0.49%	-0.29%	-29.04%
SOLARA	54 Neutral	₹21.63B	-36.05	―	―	-4.18%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	49 Neutral	₹17.66B	-18.14	―	0.08%	-2.81%	-444.69%
ZOTA	41 Neutral	₹33.29B	-40.91	―	0.06%	82.58%	-63.05%

Nureca Ltd. Corporate Events

Nureca Resubmits Q3 FY26 Investor Presentation After Updating Registered Office Address

Nureca Limited has informed the stock exchanges that it has resubmitted its investor presentation for the third quarter of fiscal year 2025-26 to reflect an updated registered office address in Andheri West, Mumbai. The company clarified that apart from correcting the registered address in the presentation, no other details related to its financial performance or disclosures for the quarter have been changed, indicating that the update is purely administrative with no operational or financial implications for stakeholders.

Nureca Releases Q3 FY26 Investor Presentation Following Unaudited Results Filing

Nureca Limited has released an investor presentation for the third quarter of fiscal year 2026, following the submission of its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, to the stock exchanges in compliance with SEBI listing regulations. The Q3 FY26 investor presentation is intended to provide shareholders and market participants with a detailed view of the company’s financial performance and operational updates, supporting transparency and informed decision-making for stakeholders.

Exchange Seeks Clarification From Nureca on Q2 FY26 XBRL Financials

The stock exchange has requested clarification from Nureca Ltd. regarding its financial results for the quarter ended 30 September 2025, specifically citing discrepancies in the XBRL-formatted submissions under Regulation 33 of SEBI’s listing obligations and disclosure requirements. The company’s response is still awaited, leaving investors and other stakeholders without clarity for now on the nature or materiality of the discrepancies and potentially heightening scrutiny of Nureca’s financial reporting practices until the matter is resolved.